[{"Assets_0_FY_USD":1320700000.0,"CommonStockSharesConverted_0_FY_shares":80000000.0,"CommonStockSharesOutstanding_0_FY_shares":80000000.0,"EarningsPerShareBasic_4_FY_USD":-0.35,"EarningsPerShareDiluted_4_FY_USD":-0.35,"NetCashProvidedByUsedInOperatingActivitiesConverted_4_FY_USD":18200000.0,"NetIncomeLossConverted_4_FY_USD":-27200000.0,"RevenuesConverted_4_FY_USD":690600000.0,"StockholdersEquity_0_FY_USD":967800000.0,"StockholdersEquityConverted_0_FY_USD":967800000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":78000000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":78000000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-K","period":"20211231","fy":"2021.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20220225"}]